EGFR-TKI

Phase 3Small molecule

SShanghai Pulmonary Hospital, Shanghai, China

EGFR-TKI is one of 122 small molecule programs targeting Metastasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Lung CancerActive, not recruiting

AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MetastasisPhase 3

Active, not recruiting

Lung CancerPreclinical

Active, not recruiting

AdenocarcinomaPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

EGFR-TKI

SShanghai Pulmonary Hospital, Shanghai, China

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

REGN2810

Regeneron

Preclinical

1 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Advanced NSCLC

NCT04324164

Q3 2031

Not yet recruiting

Lung Cancer

NCT07338396

Clinical

Trials by Indication[1]

EGFR Mutation2 trials

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT03002844·50 enrolled

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 3·NCT02859077·100 enrolled

Hypofractionated Radiotherapy1 trial

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Unknown status·FFirst People's Hospital of Hangzhou·Phase 2·NCT02788058·76 enrolled

Treatment1 trial

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03389256·144 enrolled

Adenocarcinoma1 trial

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Unknown status·SShanghai University of Traditional Chinese Medicine··NCT01745302·470 enrolled

Metastasis1 trial

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Unknown status·SSun Yat-sen University·Phase 3·NCT02714010·601 enrolled

6 more indications

Recruiting·HHunan Province Tumor Hospital··NCT04324164·800 enrolled

Non-Small Cell Lung Cancer1 trial

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

Completed·TTaichung Veterans General Hospital··NCT07267247·100 enrolled

Pneumonitis1 trial

Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology··NCT07036016·67,818 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for EGFR-TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EGFR-TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EGFR-TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

EGFR-TKI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2031

Trials by Indication[1]

EGFR Mutation2 trials

Hypofractionated Radiotherapy1 trial

Treatment1 trial

Adenocarcinoma1 trial

Metastasis1 trial

Targeted Therapy1 trial

Lung Cancer1 trial

Brain Metastases1 trial

Advanced NSCLC1 trial

Non-Small Cell Lung Cancer1 trial

Pneumonitis1 trial

References

Drug Info

Quick Facts

Related News